XELOX双周方案治疗晚期胃肠癌的近期疗效

doi:10.3971/j.issn.1000-8578.2010.11.026

XELOX双周方案治疗晚期胃肠癌的近期疗效

Effect of Oxaliplatin Combined with Capecitabine(XELOX) Biweekly in Patients with Advanced Gastrointestinal Cancer

摘要

摘要: 目的观察奥沙利铂联合卡培他滨(XELOX)双周方案治疗晚期胃、结直肠癌的临床疗效和不良反应。方法 46例晚期胃、结直肠癌患者应用奥沙利铂85mg/m2，静滴2h，d1；卡培他滨（900～1000）mg/m2，一日分两次，口服，d1～10；14d为1周期，4周期评价疗效。结果 46例均可评价疗效，CR 4例，PR 24例，RR 65.2％；不良反应主要为I～Ⅱ度血液学毒性，恶心、呕吐，末梢神经异常及手足综合征。结论奥沙利铂联合卡培他滨(XELOX)双周方案治疗晚期胃、结直肠癌疗效确切，耐受性好，值得临床推广应用。

Abstract: Objective To assess the efficacy and tolerability of oxaliplatin combination capecitabine (XELOX)biweekly in patients with advanced gastrointestinal cancer．Methods 46 patients with advanced gastrointestinal cancer were treated with oxaliplatin 80 mg／m2 ivgtt d1 in 2 hours and capecitabine(XELOX) 900～1000mg/m2 bid，po d1~10．14 days was one cycle．The effect was evaluated after four cycles．Results All cases were evaluated，4 cases were complete response and 24 cases were partial response．The overall response rate was 65.2%．The main adverse effects were grade Ⅰ-Ⅱ hematological toxicity，nausea and vomit，peripheral neuropathy and hand-foot syndrome．Conclusion The combination of capecitabine and oxaliplatin (XELOX) is an effective and better tolerated treatment in advanced gastrointestinal cancer and can yield promising clinical application．

HTML全文

参考文献(0)

施引文献

资源附件(0)